Paper2136707
Identification of HIV-1 vpr product and function.
Cohen EA and 5 others. J Acquir Immune Defic Syndr (1988), 1990. Cited by 273 papers, by iCite.
Cite this record
ConductScience Library. Identification of HIV-1 vpr product and function. Papers, record 2136707. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2136707
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| HIV-1 | Major topic |
| Proviruses | Major topic |
| Retroviridae Proteins | Major topic |
| Viral Regulatory and Accessory Proteins | Major topic |
| Cytopathogenic Effect, Viral | |
| Gene Products, vpr | |
| Trans-Activators | |
| Virus Replication | |
| vpr Gene Products, Human Immunodeficiency Virus |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| A124845 | PHS HHS | United States | PubMed | |
| A128785 | PHS HHS | United States | PubMed | |
| CA44480 | NCI NIH HHS | United States | PubMed |
Source PubMed
Cited by138
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 273 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42427503 | CD56dimCD16dim NK cells are the dominant effector cells against HIV-infected primary T-cells. | bioRxiv | 2026 | https://conductscience.org/library/papers/42427503 | PubMed |
| 40901928 | HIV-1 accessory protein Vpr possesses a cryptic p300-dependent transcription-promoting activity that is blocked by histone deacetylases in CD4+ T cells. | PLoS Pathog | 2025 | https://conductscience.org/library/papers/40901928 | PubMed |
| 40632811 | HIV-1 Vpr orchestrates ciTRAN upregulation through TGF-β induction. | PLoS Pathog | 2025 | https://conductscience.org/library/papers/40632811 | PubMed |
| 39459974 | The HIV-1 vpr R77Q Mutant Induces Apoptosis, G2 Cell Cycle Arrest, and Lower Production of Pro-Inflammatory Cytokines in Human CD4+ T Cells. | Viruses | 2024 | https://conductscience.org/library/papers/39459974 | PubMed |
| 34562223 | HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments. | Cell Mol Neurobiol | 2022 | https://conductscience.org/library/papers/34562223 | PubMed |
| 32753492 | HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair. | mBio | 2020 | https://conductscience.org/library/papers/32753492 | PubMed |
| 31776272 | HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity. | J Virol | 2020 | https://conductscience.org/library/papers/31776272 | PubMed |
| 31652959 | Vpr and Its Cellular Interaction Partners: R We There Yet? | Cells | 2019 | https://conductscience.org/library/papers/31652959 | PubMed |
| 30809215 | HUSH, a Link Between Intrinsic Immunity and HIV Latency. | Front Microbiol | 2019 | https://conductscience.org/library/papers/30809215 | PubMed |
| 29743354 | Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1. | J Virol | 2018 | https://conductscience.org/library/papers/29743354 | PubMed |
| 28424288 | Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells. | J Virol | 2017 | https://conductscience.org/library/papers/28424288 | PubMed |
| 28075409 | The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28075409 | PubMed |
| 27775563 | Where in the Cell Are You? Probing HIV-1 Host Interactions through Advanced Imaging Techniques. | Viruses | 2016 | https://conductscience.org/library/papers/27775563 | PubMed |
| 27440900 | HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling. | J Virol | 2016 | https://conductscience.org/library/papers/27440900 | PubMed |
| 26511606 | Fluorescent protein-tagged Vpr dissociates from HIV-1 core after viral fusion and rapidly enters the cell nucleus. | Retrovirology | 2015 | https://conductscience.org/library/papers/26511606 | PubMed |
| 24912982 | Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest. | Virol J | 2014 | https://conductscience.org/library/papers/24912982 | PubMed |
| 24049167 | An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. | J Virol | 2013 | https://conductscience.org/library/papers/24049167 | PubMed |
| 23986795 | T-Cell Signaling in HIV-1 Infection. | Open Virol J | 2013 | https://conductscience.org/library/papers/23986795 | PubMed |
| 23982958 | YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment. | J Neurovirol | 2013 | https://conductscience.org/library/papers/23982958 | PubMed |
| 23849790 | The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. | Virology | 2013 | https://conductscience.org/library/papers/23849790 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2136707
GET https://conductscience.org/api/papers/v1/2136707/cited_by?page=2